However, the FDA repeatedly stated it "cannot determine the adequacy" of many responses or found them "not adequate." Regulatory consequences FDA warned that "failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice
In general, prior authorization can be obtained for some of the GLP-1 agonists if you and your healthcare provider can prove they are medically necessary and you meet certain criteria
Other options in the GLP-1 space include combination approaches
The implications of centrally produced, neuromodulatory GLP-1 in the context of GLP-1RAs are uncertain, as the degree to which signals from pre-proglucagon neurons/endogenous GLP-1 system and GLP-1RA activity converge on shared downstream targets is unclear 6 and may in fact occur independently 7
Semaglutide and the risk of diabetic retinopathycurrent perspective
Wish I didn't have to do that, but when this stuff works it works well, and I haven't had any of the bad side effects my friends have had on the injections